1-3 of 3
Mace L. Rothenberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B072: CURE-PROs: Proof-of-mechanism for the first reversible self-assembling targeted protein degraders

Free
Sarah F Giardina, Elena Valdambrini, Micheal Peel, Manny D Bacolod, Mace L Rothenberg, Richard B Lanman, J David Warren, Francis Barany
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B072.
https://doi.org/10.1158/1535-7163.TARG-23-B072
Published: 01 December 2023
View articletitled, Abstract B072: CURE-PROs: Proof-of-mechanism for the first reversible self-assembling targeted protein degraders
Journal Articles

Abstract A33: CuraBase: An integrated relational database and online collaboration platform for cancer drug development

Free
William Husler, Mehdi Nosrati, Mace L. Rothenberg, W. Michael Korn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A33.
https://doi.org/10.1158/1535-7163.TARG-09-A33
Published: 10 December 2009
View articletitled, Abstract A33: CuraBase: An integrated relational database and online collaboration platform for cancer drug development
Journal Articles

Silatecan DB-67 is a novel DNA topoisomerase I–targeted radiation sensitizer

Free
Allan Y. Chen, Shyh-Jen Shih, Liza N. Garriques, Mace L. Rothenberg, Michael Hsiao, Dennis P. Curran
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (2): 317–324.
https://doi.org/10.1158/1535-7163.317.4.2
Published: 15 February 2005
View articletitled, Silatecan DB-67 is a novel DNA topoisomerase I–targeted radiation sensitizer
Open the PDF for Silatecan DB-67 is a novel DNA topoisomerase I–targeted radiation sensitizer in another window